Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback